---
title: "Weekly Recap | Abbvie +6.21%, closing in on record highs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296674248.md"
description: "AbbVie (ABBV) closed the week at $264.96, up 6.21%, handily outpacing the S&P 500 by roughly 7.64 percentage points as the broad market slipped 1.43%. The rally was broad-based: shares opened Monday at $249.49 and steadily climbed, with the bulk of gains landing on Tuesday and Wednesday when the stock hit a weekly high of $266.97. A mild pullback on Thursday and Friday did little to erase the advance, leaving the stock near the top of its recent range with a weekly amplitude of 7.48%."
datetime: "2026-08-22T06:53:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296674248.md)
  - [en](https://longbridge.com/en/news/296674248.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296674248.md)
generator: "portal-rs"
---

# Weekly Recap | Abbvie +6.21%, closing in on record highs

## The Week

AbbVie (ABBV) closed the week at $264.96, up 6.21%, handily outpacing the S&P 500 by roughly 7.64 percentage points as the broad market slipped 1.43%. The rally was broad-based: shares opened Monday at $249.49 and steadily climbed, with the bulk of gains landing on Tuesday and Wednesday when the stock hit a weekly high of $266.97. A mild pullback on Thursday and Friday did little to erase the advance, leaving the stock near the top of its recent range with a weekly amplitude of 7.48%.

## Key Events

The week’s narrative centred on the growing profile of AbbVie’s neuroscience pipeline and the financing behind its M&A ambitions. Management signalled that neuroscience is becoming a quiet powerhouse, eyeing $12.7 billion in sales this year. On Wednesday, the company closed a $10 billion multi-tranche senior notes offering to fund the Apogee deal, underscoring the capital heft behind its deal-making strategy.

A separate filing showed EVP and Chief Business & Strategy Officer Nicholas Donoghoe disposed of 32,710 shares valued at roughly $8.18 million. On the pipeline front, AbbVie confirmed it will present new data from its lung cancer portfolio at the upcoming 2026 World Conference on Lung Cancer (WCLC), keeping the R&D catalyst story alive.

## Analyst Ratings

Coverage remains lopsidedly positive. Of 31 analysts, 17 rate the stock a buy, 8 overweight, 5 hold and 1 underweight; none tag it as sell. The consensus recommendation is a buy with a target price of $276.59, a premium of about 4.39% to the latest close. Target estimates range from $200 to $328, suggesting some dispersion in long-term value assumptions. AbbVie ranks third among 505 biotech firms tracked in the industry.

## The Week Ahead

A busy macro calendar awaits, with the FHFA Housing Price Index, Case-Shiller home-price data, consumer confidence and new home sales all due on Tuesday. For AbbVie, the focus shifts to any incremental detail out of the WCLC presentation and clues on how the Apogee integration progresses following the $10 billion bond raise.

## In Short

AbbVie logged a standout week, lifted by a bullish neuroscience sales outlook and the clean execution of a sizeable debt offering. The analyst consensus sits firmly in buy territory, and the stock’s industry ranking is among the elite. Small counterweights—an executive share sale and some institutional position trimming—did not derail sentiment. The next leg hinges on whether pipeline data can validate the premium and whether macro readings keep risk appetite intact.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Massachusetts Financial Services Co. MA Reduces Stock Position in AbbVie Inc. $ABBV](https://longbridge.com/en/news/296592574.md)
- [Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV](https://longbridge.com/en/news/296462167.md)
- [Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?](https://longbridge.com/en/news/296816441.md)
- [AbbVie Inc. $ABBV Shares Sold by Capital Investment Advisory Services LLC](https://longbridge.com/en/news/296190656.md)
- [AbbVie EVP, Chief Business and Strategy Officer Nicholas Donoghoe disposes of 32,710 common shares worth $8.18 million](https://longbridge.com/en/news/296270161.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**